Discounted Cash Flow (DCF) Analysis Levered

Orphazyme A/S (ORPH)

$ 4.84
-0.13 (-2.63%)

Free Cash Flow

Year
A/P
2015
Projected
2016
Projected
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue -----------
Revenue (%)
Operating Cash Flow -----------
Operating Cash Flow (%)
Capital Expenditure -----------
Capital Expenditure (%)
Free Cash Flow -----------

Weighted Average Cost Of Capital

Share price $ 4.84
Beta 0.706
Diluted Shares Outstanding 20
Cost of Debt
Tax Rate 0.30
After-tax Cost of Debt 4.98%
Risk-Free Rate
Market Risk Premium
Cost of Equity 8.080
Total Debt 57.18
Total Equity 96.81
Total Capital 153.99
Debt Weighting 37.13
Equity Weighting 62.87
Wacc

Build Up Free Cash Flow

Year
A/P
2015
Projected
2016
Projected
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue -----------
Operating Cash Flow -----------
Capital Expenditure -----------
Free Cash Flow -----------
WACC
PV LFCF -----------
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 6.93
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -669.75
Equity Value -
Shares Outstanding 20
Equity Value Per Share -